Literature DB >> 28787279

Myxoid Mesenchymal Tumors of the Uterus: An Update on Classification, Definitions, and Differential Diagnosis.

Aurelia Busca1, Carlos Parra-Herran.   

Abstract

Tumors with a predominant myxoid stroma are rare in the uterus. When encountered, however, they pose a diagnostic challenge. Traditionally myxoid leiomyosarcoma has been the most important consideration in this category, given its adverse prognosis and deceptively bland morphology. Conventional features of malignancy are variably present; in contrast, an infiltrative tumor border is a consistent pathologic characteristic. More recently, previously under-recognized lesions have been identified, in part due to our growing knowledge of their underlying molecular alterations: uterine inflammatory myofibroblastic tumor frequently harbors ALK rearrangements and a novel ZC3H7B-BCOR gene fusion has been described in a subset of myxoid high-grade endometrial stromal sarcomas. These tumors need to be distinguished from myxoid leiomyosarcoma, as by comparison have a less aggressive course and are amenable to targeted treatments. In addition, uterine mesenchymal tumors with malignant potential need to be distinguished from benign tumors and epithelial and mixed malignancies. This review aims to discuss our current understanding of the most common uterine myxoid neoplasms: their clinical features, their distinguishing histopathologic, immunohistochemical, and molecular features and the clues and pitfalls in their diagnosis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28787279     DOI: 10.1097/PAP.0000000000000164

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  4 in total

Review 1.  Uterine myxoid leiomyosarcoma - a rare malignant tumor: the role of complex morphopathological assay. Review and case presentation.

Authors:  Anca Maria Istrate-Ofiţeru; George Lucian Zorilă; Dan Ruican; Ana Maria Petrescu; Elena Iuliana Anamaria Berbecaru; Gabriela Camelia Roşu; Răzvan Grigoraş Căpitănescu; Rodica Daniela Nagy; Liliana Cercelaru; Antonie Edu; Dominic Gabriel Iliescu; Roxana Cristina Drăguşin
Journal:  Rom J Morphol Embryol       Date:  2021 Oct-Dec       Impact factor: 0.833

2.  Surgery Treatment Improved the Overall Survival Rate in Locoregional Myxoid Leiomyosarcoma than Other Myxosarcomas in the United States.

Authors:  Marwan Almoiliqy; Abdullah Al-Danakh; Mohammed Safi; Mohammed Alradhi; Mahmoud Al-Azab; Salah Adlat; Wanhai Zhou; Aiman Saleh A Mohammed; Ahmed Al-Maamari
Journal:  Oxid Med Cell Longev       Date:  2021-04-30       Impact factor: 6.543

3.  Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.

Authors:  Martee L Hensley; Shweta S Chavan; Mark T A Donoghue; David M Hyman; David B Solit; Rajmohan Murali; Robert Soslow; Sarah Chiang; Achim A Jungbluth; Chaitanya Bandlamudi; Preethi Srinivasan; William D Tap; Evan Rosenbaum; Barry S Taylor
Journal:  Clin Cancer Res       Date:  2020-04-16       Impact factor: 13.801

4.  Ovarian mucinous tumors with mural nodules: immunohistochemical and molecular analysis of 3 cases.

Authors:  Ying Shao; Qin Liu; Haiyan Shi; Bingjian Lu
Journal:  Diagn Pathol       Date:  2020-04-14       Impact factor: 2.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.